Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer

Journal of Medical Genetics

Volumn 42, Issue 6, 2005, Pages 479-484

  Zhang, X ^b,c   Miao, X ^b   Sun, T ^b   Tan, W ^b   Qu, S ^b   Xiong, P ^d   Zhou, Y ^b   Lin, D ^a,b  

^a CANCER HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c NORTH CHINA COAL MEDICAL COLLEGE   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CELL DEATH; CONTROLLED STUDY; DNA POLYMORPHISM; ESOPHAGUS CANCER; FAS GENE; FASL GENE; FEMALE; GENE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

AGED; ANTIGENS, CD95; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTORS;

EID: 20544473024     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.030106     Document Type: Article

References (42)

1. Evan GI, Vousden KH, Proliferation. cell cycle and apoptosis in cancer. Nature 2001;17:342-8.
2. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
3. Tgney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukocyte Biol 2002;71:907-20.
4. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
5. Griffith TS, Ferguson TA. The role of FasL-induced apaptosis in immune privilege. Immunol Today 1997;18:240-4.
6. Nagato S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
7. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-25.
8. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
9. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999;27:3068-72.
10. Gartas C, Tohmoa Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998;58:2057-62.
11. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-64.
12. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tumors with overexpression of FasL in small cell lung carcinoma. J pathol, 2003;201:268-77.
13. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60.
14. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
15. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
16. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999;125:73-84.
17. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 2001;127:20-6.
18. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998;187:1825-8.
19. Peters AM, Kohfink B, Martin H, Griesinger F, Wormann B, Gahr M, Roesler J. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphopproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol 1999;27:868-74.
20. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999;27:3068-72.
21. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60.
22. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagato S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
23. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
24. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30.
25. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP. A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-8.
26. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 2004;96:1030-6.
27. Yang L, Parkin DM, Li L, Chen Y. Time trend in cancer mortality in China. Int J Cancer 2003;106:771-83.
28. Chen ZM, Xu Z, Collis R, Li WY, Peto R. Early health effects of the emerging tobacco epidemic in China. A 16-years prospective study. JAMA 1997;278:1500-4.
29. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, Campbell TC, Chen JS. Emerging tobacco hazards in China. 1. Retrospective proportional mortality study of one million deaths. Br Med J 1998;317:1411-22.
30. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press, 2001.
31. Kleinerman R, Wang Z, Lubin J, Zhang S, Metayer C, Brenner A. Lung cancer and indoor air pollution in rural China. Ann Epidemiol 2000;10:469.
32. Metayer C, Wang Z, Kleinerman RA, Wang L, Brenner AV, Cui H, Cao J, Lubin JH. Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. Lung Cancer 2002;35:111-17.
33. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, Lin D. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003;105:669-73.
34. In: Kleinbaum DG, Kupper LL, Morgenstern H, eds. Epidemiologic research: principles and quantitative methods. London: Lifetime Learning Publications, 1982.
35. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999;25:48-53.
36. Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest 2001;31:550-3.
37. Pugh BF, Tjian R. Mechanism of transcriptional activation by Sp1: evidence for coactivators. Cell 1995;61:1187-97.
38. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221-5.
39. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003;42:1-8.
40. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
41. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 2001;127:20-6.
42. Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ. Fas (CD95/APO-1) and Fas ligand expression in normal poncreas and poncreatic tumors. Implications for immune privilege and immune escape. Cancer 2002;94:2552-60.